OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:58 UTC. Every row links to its source record.

PAX5 paired box 5

ENSG00000196092 · protein coding · Open Targets profile

Transcription factor that plays an essential role in commitment of lymphoid progenitors to the B-lymphocyte lineage (PubMed:10811620, PubMed:27181361). Fulfills a dual role by repressing B-lineage inappropriate genes and simultaneously activating B-lineage- specific genes (PubMed:10811620, PubMed:27181361). In turn, regulates cell adhesion and migration, induces V(H)-to-D(H)J(H) recombination, facilitates pre-B-cell receptor signaling and promotes development to the mature B-cell stage (PubMed:32612238). Repression of the cohesin- release factor WAPL causes global changes of the chromosomal architecture in pro-B cells to facilitate the generation of a diverse antibody repertoire (PubMed:32612238). {ECO:0000269|PubMed:10811620, ECO:0000269|PubMed:27181361, ECO:0000269|PubMed:32612238}.

In 14 of 15 cancers, the evidence for PAX5 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751leukemia, acute lymphoblastic, suscepti…leukemia, acute lymphoblastic, susceptibility to, 3leukemia, acute lymphoblastic, susceptibility to, 3: germline 0.62acute lymphoblastic leukemiaacute lymphoblastic leukemiaacute lymphoblastic leukemia: somatic 0.64acute lymphoblastic leukemia: germline 0.58prostate adenocarcinomaprostate adenocarcinomaprostate adenocarcinoma: somatic 0.53B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemia: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61lung carcinomalung carcinomalung carcinoma: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61superficial spreading melanomasuperficial spreading melanomasuperficial spreading melanoma: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61nodular malignant melanomanodular malignant melanomanodular malignant melanoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61breast ductal adenocarcinomabreast ductal adenocarcinomabreast ductal adenocarcinoma: somatic 0.61esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
Med-Quality Pocket
PROTAC
Half-life Data

gnomAD loss of function constraint: o/e 0.20590999722480774 (upper bound 0.3593299984931946). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of PAX5's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of PAX5's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.